

Anti-Toxin B (Bezlotoxumab), Human IgG1 Antibody

09/20

CATALOG NO.: A2220-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a human monoclonal antibody that targets *Clostridium difficile* toxin B. Toxin B (TcdB) is a glucosyltransferase protein that glucosylates small GTPases such as Rho, Rac, and Cdc42 in the target cells. The toxin is known to disrupt the actin cytoskeleton of the cells by causing condensation of the actin, blebbing of the membrane, which eventually leads to apoptosis and cell death. The antibody binds to the two epitopes on the N-terminal of the Toxin B CROP domain via its two Fab regions, thus partially blocking carbohydrate-binding pockets and prevents the binding of the toxin to the host cells. The original monoclonal antibody was approved by the FDA to treat adult patients who are either receiving antibacterial treatment for *Clostridium difficile* infection (CDI) or are at a high risk of getting re-infected with CDI.

ALTERNATE NAMES: MBL-CDB1, MK-6072, CDB-1, MDX-1388, MK-3415A, tcdB, glycosylating toxin TcdB

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: Recombinant / IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: *Clostridium difficile* Toxin B

CAS NUMBER: 1246264-45-8

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: *Clostridium difficile*

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-IL-1 β (Canakinumab), Human IgG1 Antibody (A2144)
 Anti-RSV (Felvizumab), Human IgG1 Antibody (A1446)
 Anti-RSV (Palivizumab), Humanized Antibody (A2166)
 Anti-VEGF (Bevacizumab), Humanized Antibody (A1045)
 Anti-IL-5R α (Benralizumab), Humanized Antibody (A2162)

FOR RESEARCH USE ONLY! Not to be used on humans.